teprotumumab-trbw (Tepezza)
Jump to navigation
Jump to search
Indications
- treatment of proptosis of thyroid eye disease
Contraindications
* pregnancy prevention for 6 months following last dose of Tepezza
Dosage
- 10 mg/kg IV initially
- follow with 20 mg/kg IV q3 weeks for 7 additional infusions
- 500mg/single-dose vial
Pharmacokinetics
- no dosages adjustment for renal failure
Adverse effects
- nausea, diarrhea, dysgeusia
- alopecia, hyperglycemia, hearing loss, dry skin
- muscle spasm, headache, fatigue,
More general terms
References
- ↑ FDA News Release. January 21, 2020 FDA approves first treatment for thyroid eye disease https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease
- ↑ Rothaus C Teprotumumab for Thyroid Eye Disease. NEJM Resident 360. Ja 22, 2020 https://resident360.nejm.org/clinical-pearls/teprotumumab-for-thyroid-eye-disease
- ↑ Strawbridge JC et al. Google searches for thyroid eye disease after regulatory approval of teprotumumab. JAMA Ophthalmol 2022 Apr 28; PMID: https://www.ncbi.nlm.nih.gov/pubmed/35482336 PMCID: PMC9052105 (available on 2023-04-28) https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2791596
- ↑ Medscape: teprotumumab (Rx) https://reference.medscape.com/drug/tepezza-teprotumumab-4000026